

Host Genetics in Dermatophytosis: Implications for Disease Mechanism and Management

Matthew Donovan^{1,2}

¹ Department of Bioengineering, King Fahd University of Petroleum and Minerals (KFUPM), Dhahran 31261, Saudi Arabia.

² Interdisciplinary Research Center for Hydrogen and Energy Storage (IRC-HES), King Fahd University of Petroleum and Minerals (KFUPM), Dhahran, 31261, Saudi Arabia.

Abstract

Because dermatophytes and their hosts are so different, infection susceptibility is most likely the consequence of changes on both sides, as well as reciprocal adaptation. In addition, some studies have revealed a role for host genetics in the development of illness, including possible Mendelian inheritance patterns for dermatophytosis tendency. This paper emphasizes the complexity of the genetic link between dermatophytes and their natural and accidental hosts. According to a literature study, different ideas and methodologies may lead to different interpretations of this connection. Selecting an appropriate model for analysis and reasoning is a critical step in better understanding these disorders. A significant portion of the research is focused on the host's genetic and immunological response to dermatophyte infection. Future studies will require a broader exploration of the dermatophyte genome in combination with analysis of large phenotypically well-characterized populations of various dermatophyte species in order to identify the main factors mediating infection risk that can be targeted to disrupt host–pathogen interactions and used in therapies. As a result, both conceptually and practically, extensive study on the interactions between dermatophytes and their specific hosts, which comprise intricate molecular pathways, is critical. However, it is undeniable that genetic predisposition plays a crucial role in the susceptibility to dermatophyte infection.

Introduction

Dermatophytosis is a common illness that affects 20–25 percent of the human population every year (1,2,3). Dermatophytes, filamentous fungi with a strong affinity for keratinized tissues such as skin, hair, and nails, are the main etiological agents of this illness (1, 4,5,6). *Trichophyton*, *Microsporum*, and *Epidermophyton* were previously designated as the causal agents of dermatophytosis in the order Onygenales (7). Molecular phylogenetic techniques, on the other hand, have changed dermatophyte taxonomy, proving that *Trichophyton* is a polyphyletic taxon and allowing for the introduction of new taxa such as *Nannizzia*, *Arthroderma*, *Paraphyton*, *Lophophyton*, *Ctenomyces*, and *Guarromyces* (8).

Over the last two decades, the global incidence of dermatophytosis has increased dramatically. Socioeconomic issues, large-scale worldwide travel, immigration from tropical countries, climate change, and regular interaction with animals, particularly pets, are all contributing factors (9,10,11,12). As a result of prolonged life and the unavoidable use of immunosuppressive medicines by many patients, dermatophytosis-induced morbidity has increased in humans (13,14,15). Furthermore, because the majority of dermatophytes are zoonotic, intimate contact with pets increases the risk of infection. As a result, it appears that only an interdisciplinary strategy comprising dermatologists, pediatricians, primary care physicians, mycologists, and veterinarians can assist to control the spread of dermatophytoses in today's world (16). The significance of genetic variables in the tendency to dermatophytosis and the possible inheritance of these tendencies is a fascinating topic.

We explain current results concerning the mechanism of dermatophyte infections in this review, with an emphasis on the disease's hereditary propensity in humans. The importance of heredity in families with a high incidence of dermatophyte infections, as well as unique host–pathogen interactions, are underlined in particular.

Determinants of Dermatophytosis Prevalence: Genetic Predisposition

Interestingly, data from several observational studies indicate that dermatophytes infect people of all ages, races, genders, and socioeconomic statuses at alarmingly high rates (17,18,19). The incidence of superficial fungal infections, however, varies greatly. The factors that influence dermatophyte infection susceptibility and frequency may be separated into three categories: (1) environmental factors that affect both the host and the pathogen, (2) host-specific factors, and (3) dermatophyte species and ecological group factors (1, 10, 20, 21). Climate conditions, such as humidity and temperature, are included in the first category (1, 5, 20,21,22,23). The host is largely dependent on genetic susceptibility to infectious diseases, as well as other factors such as age, sex, maceration of the epidermis, mechanical skin lesions, impairment of immunological barriers, and possible interactions with dermatophytes and their spores associated with socioeconomic status and profession (18, 23,24,25,26,27,28). Finally, the ecological niche filled by the fungus has a substantial influence on the course of infection (23, 24, 29,30,31).

The symptoms of dermatophyte infection are not limited to chronic or acute superficial lesions, but can range from individuals who are never infected to those who have inflammatory, non-inflammatory, or treatment-resistant symptoms to cases of invasive, disseminated, and life-threatening disease (14, 17, 32,33,34,35,36,37,38).

The acquisition of dermatophyte infectious components by the host's stratum corneum is not synonymous with the emergence of infection symptoms, according to conclusive data from observational studies (10, 39, 40). Furthermore, despite the harmful character of the dermatophytes, the frequency of cutaneous fungal infections is not as great as one might assume (1, 2, 23, 41, 42). Second, the relatively high incidence of dermatophytoses in specific communities or families may be a key indicator of genetic sensitivity to these fungi. In this context, an obvious issue arises: whatever genetic characteristics in the human/animal host cause some people to be immune to illness symptoms and even stay asymptomatic carriers, while others acquire severe dermatophytosis that, at worst, can be invasive and resistant to treatment?

Pathogen Virulence or Host Genetic Predisposition

The pathophysiology of infectious illnesses has been studied for about seven decades to determine if pedigrees, polymorphism, and other genetic alterations, particularly the genetics of immunity, underpin dermatophyte susceptibility or offer protection against these infections (10, 17, 19). Although the nature and severity of dermatophyte infections, their relapses despite treatment, and the receptivity of the host physicochemical barrier to the pathogen are all influenced by the host's genetics (43), the pathogenic potential of highly ecologically diverse dermatophytes is equally important in the disease's development (37, 44, 45). The presence of animals in the home is associated with the largest number of dermatophytosis cases, and their occurrence is increasing with the growing popularity of pets globally (9, 11, 26, 46). As a result, dermatophytes found in soil have a lower virulence than animal-related infections (47, 48), and many researchers and clinicians perceive geophilic dermatophytes as opportunistic pathogens (49, 50). Anthropophilic dermatophytes, which have evolved to thrive on keratinophilic substances of human origin, are at the heart of these harmful relationships, and their high transmission is confined to humans alone (10, 51, 52). However, even within the same ecological group, dermatophyte strains exhibit significant genomic and phenotypic variability, which is due to the profile of secreted exoenzymes influencing host response (5, 29, 37, 44, 53, 54). Furthermore, because of the diversity in enzyme profiles and activity, only a few or none of them can be sufficiently pathogenic to induce clinical illness (5, 55,56,57).

Interestingly, multiple infection patterns may be seen in the same genetic dermatophyte strain (26, 29, 35, 46, 58). Different clinical presentations of dermatophytosis have also been discovered in cognate persons living or working together in several circumstances (41, 59, 60). The type and degree of the interaction established with dermatophytes after exposure seems to be influenced by the host. The choice of a research approach is critical in the study of genetic predispositions to dermatophyte infections. Initially, variations in the prevalence of symptomatic infection between genetically related family members and spouses were used to infer the genetic basis of susceptibility to dermatophytes (61,62,63,64). Many scientists, however, saw this research as dubious, arguing that the variations detected based on medical history and mycological examination could not be meaningful. Because of the high frequency of daily routine interaction in the shared living environment, which increases infection rates, research among family members is unreliable. Humans who are not related by blood but have a shared working environment or daily activities, such as in the army, school, or hospital, have a comparable incidence of dermatophytoses (41, 42, 64, 65, 66, 67, 68, 69, 70). Abdel-Rahman et al. (58) suggested in their groundbreaking study that cross-sectional sampling strategies used in most epidemiologic studies are insufficient for describing the natural course of infection and fail to identify individuals who develop active disease; thus, a different strategy for testing infection predisposition should be used. In a two-year prospective longitudinal research (58), the authors analyzed preschool-aged children who attended the same child care center. Then, molecular strain typing was used to distinguish between those who had never been infected with the pathogen, those who had acquired and lost multiple fungal strain types on a regular basis, and those who had acquired and sustained infection with the same strain type for years. A total of 3541 scalp cultures were obtained from 446 youngsters for this investigation. Each month, 22% to 51% of the scalp cultures were positive, resulting in 1390 fungal cultures and 1048 typeable cultures. In children with multiple typeable isolates, 51% had the same strain exclusively, 37% had a single predominant strain with secondary strains acquired transiently, and 12% had a distinct strain of *T. tonsurans* in each typeable culture. It was approximately 90 percent likely that the same strain would survive in later months, which was unlikely to have occurred by accident. Exclusive, predominant, and temporary *T. tonsurans* carriers had significantly varied rates of symptomatic illness. Unlike dermatophyte infections in older people, where symptomatic disease appears to be a result of pathogen acquisition and asymptomatic carriers can be linked to the index case, the infection in the preschool-age population was endemic, and symptomatic disease appeared to be triggered by a single strain that remained on the scalp.

Indeed, the form and degree of the interaction created with dermatophytes is influenced by the host's health, and the same genetic dermatophyte strain can cause distinct infection patterns in people sharing the same environment (2, 41, 58). Furthermore, various coexisting health disorders, such as eczema, psoriasis, ichthyosis, atopic dermatitis, and seborrheic dermatitis, may impact dermatophyte susceptibility (58, 71, 72, 73, 74, 75, 76). As a result, considering the genetic basis of susceptibility to dermatophyte infections without first determining the pathogenicity of the fungus does not appear to be supported by evidence. Finally, different strains of fungus with varying infective abilities may be involved, which, in combination with the host organism's genetic sensitivity, defines the sort of infection that occurs. As a result, the genetic predisposition of the host is just as significant as the pathogen's virulence and adaptability. Both aspects should be considered in clinical practice, and mycological tests should always be conducted and the findings correlated with the patient's state.

Susceptibility to Dermatophyte Infection Is Passed Down Through Generations

Regardless of the methodological flaws mentioned above, the study on the prevalence of dermatophyte infections in related persons raises questions. In the middle of the twentieth century, researchers came to conflicting findings on genetic tendencies in dermatophytoses. Genetically related family members, husbands/wives marrying into these households, and entirely unrelated persons living in the same environment all had different rates of dermatophyte infections (62, 63, 77, 78, 79). On the basis of questionnaires completed by over 100 dermatologists, Sulzberger et al. (80) examined the extent of family infections of the foot and groins. Their research found a relatively weak link between family members and the occurrence of dermatophytoses, with just four confirmed cases of familial infection among hundreds of thousands of patients evaluated; hence, such a high rate of infection was of no practical significance. The authors said that no familial infection could be established unless the fungus were isolated in culture and visually matched. The frequent interaction in a shared environment, which has been demonstrated to have an influence on infection rates in populations without genetic ties (66, 67, 78, 81), confused these associative investigations among family members. Skeptics are using the incidence of dermatophytoses in persons who live or work together as a criteria for further investigation into the genetic causes of vulnerability to these illnesses. Hopkins and Hillegas (78) observed that diverse species appeared at roughly the same proportions in most of the groups studied in their examination of fungal infections on the feet of soldiers at a military station. Individual vulnerability to a latent infection and immunity, rather than the possibility of cross-infection, were therefore prioritized. Nonetheless, the fact that three of the 26 groups evaluated in their study revealed significant variance in the major fungal species causing the illness, while others showed relatively little variation, raised questions about the correctness of the results. The inconsistencies in these results were due to the high turnover of personnel in military institutions, which did not always allow for enough time for any species to gain dominance (78).

Furthermore, contact sports have a high frequency of fungal skin infections, with tinea gladiatorum in wrestlers being a common example (70, 82). Dermatophytosis was shown to be more common among athletes under the age of 15 (82, 83). Despite continued wrestling activity, large levels of fungistatic effect of steroid hormones beyond puberty are likely to limit the occurrence of tinea gladiatorum in the older age range (83). Lewis and Lewis (64) identified healthcare staff in a rehabilitation center who had detectable physical contact and calculated that a quarter of them had a fungal infection. The significant contact group had a 33 percent infection rate and the moderate contact group had a 17 percent infection rate; the minimal contact group had no illnesses.

However, these historical data, together with examination of more refined pedigree results, give some support for a genetic link between dermatophyte infection susceptibility and genetics. Bonifaz et al. (84) came up with the first significant conclusion. The genetic predisposition to dermatophytosis was shown to be autosomal dominant in nine out of 16 family members, i.e., children with the same mother but different dads, in their investigation on confirmed instances of tinea imbricata caused by *Trichophyton concentricum*. Although Ravine et al. (85) reported autosomal recessive inheritance of tinea imbricata susceptibility in 1980, the authors firmly emphasize that the described family case clearly implies an autosomal dominant rather than recessive inheritance pattern of susceptibility. Furthermore, the genetic propensity to tinea imbricata was not entirely clarified by these contradicting data. According to Hay et al. (86), in addition to heritable vulnerability to this illness, heritable inadequate immune response to infection might also be a factor in the high recurrence rate and broad nature of clinical lesions seen in *Tinea imbricata*. Dey and Maplestone (87), Polunin (88), and Reid (89) found a significantly greater frequency of tinea imbricata in various races living in the same nation and under similar environmental conditions, indicating that racial traits play a role in disease susceptibility. The findings of racial disparities in infection rates might be the consequence of ethnically driven environmental variations between racial groups of persons living in close proximity.

Furthermore, Zaias et al. (90) discovered that the autosomal dominant pattern of inheritance was significant in increasing sensitivity in pedigrees of families in Italy with distal subungual onychomycosis and associated tinea pedis produced in foot soles by *T. rubrum*. In addition, infections in family members with inherited predisposition were equally common in both sexes. Families in France made similar discoveries about onychomycosis tendencies being passed down over the generations. Onychomycosis is intriguing in another way, in terms of genetic proclivities: in almost half of cases identified in children, parents were also afflicted, implying hereditary predispositions (19).

A breakdown in the immune response has also been hypothesized as a reason for variation in dermatophyte susceptibility in various studies. CARD9 (caspase recruitment domain-containing protein 9) deficiency due to compound heterozygous mutations is a differential diagnosis for severe, deep, recurring cutaneous fungal infections in individuals who are non-immunosuppressed or do not receive immunosuppressive medication (91,92,93). CARD9 is an adapter protein that regulates macrophage and neutrophil antifungal activity in the skin (91).

This impairment is also inherited as an autosomal recessive trait (94). CARD9 is also required for the activation of T-helper 17 (Th17) cells, which is mediated mostly by dectin-2, but also by dectin-1 signaling, macrophage-inducible C-type lectin, and maybe additional immune-related receptors (95,96,97). Glocker et al. (98) conducted a pedigree study on a consanguineous family with multiple members suffering from chronic fungal infections and a CARD9 autosomal recessive inheritance mechanism. Recurrent fungal infections were identified clinically in eight family members in their investigation, three of whom died as children. There were no uncommon bacterial or viral illnesses in any of these individuals, indicating that the host's resistance against these pathogens was normal. Furthermore, Nazarian et al. (93) discovered a tinea profunda case in a 31-year-old male caused by *Trichophyton rubrum* and *Trichophyton violaceum* and linked to biallelic mutations in CARD9. Deep dermatophytosis accounted for 37.3 percent of all documented instances of fungal infections connected to CARD9 deficiency owing to autosomal recessive mutations, according to Vaezi et al. (96). These dermatophytoses were found to be caused by *Trichophyton violaceum*, *Trichophyton rubrum*, and *Trichophyton mentagrophytes* (93, 99,100,101). Surprisingly, analyses of the characteristics, distribution, frequency, and relationship between the genotype of the CARD9 gene mutations and fungal infections in the reported cases revealed that dermatophytosis caused by this factor accounted for up to 75% of African cases (96), which is likely reflected in the high prevalence of *T. violaceum* isolation on this continent (48, 102). These findings show that mutations may be particular to particular populations or geographic locations where numerous closed groups have a high percentage of consanguinity.

The adaptive immune response to dermatophytosis has been extensively examined in geographically separated groups of patients (75, 103, 104, 105, 106, 107). In the course of fungal infection, the major histocompatibility complex (MHC) and the HLA (Human Leukocyte Antigen) system are thought to be crucial for antigen presentation and activation of T cell-mediated responses (75). Zaitz et al. (103) discovered HLA-DR4 in 100 percent of persons without symptoms and 25 percent of cases in a Brazilian Ashkenazi Jewish community with *T. rubrum* onychomycosis, showing a preventive effect against disease susceptibility. In turn, Garca-Romero et al. (104) discovered a greater frequency of HLA-DR8 in families with onychomycosis caused by the same dermatophyte species in a Mexican mestizo community, suggesting that this haplotype may confer vulnerability. Carrillo-Meléndrez et al. (75) also discovered a link between HLA-DR8 and the genetic predisposition to onychomycosis in nail psoriasis patients. Their research also demonstrated a link between HLA-DR1 and a genetic tendency to develop onychomycosis.

The incidence of specific disease entities linked with this group of fungus is significantly higher when the genetic factor is implicated, according to this retrospective investigation of the hereditary determinants of dermatophytoses susceptibility. Furthermore, the spatial component of these partnerships involving human races living in close proximity to one another is beginning to emerge. In addition, identifying high-risk households will allow family members to be educated about the dangers of fungal diseases. As a result, in practical practice, the information gathered during the interview can help to speed up the diagnosis and motivate the dermatologist to prescribe the proper treatment.

An overly broad approach to dermatophytosis as a whole, as well as the use of approaches based only on infection frequency analysis, on the other hand, is inaccurate and leads to incorrect conclusions about genetic predisposition.

Identification of Susceptibility-Related Genes

The assertion that genetic vulnerability to dermatophytosis is a monogenic trait can be just as misleading as the current tendency of emphasizing the importance of genetic determinants while ignoring other host, pathogen, or environmental variables. The search for genetic dependencies while neglecting non-inherited variables is one of the major shortcomings of investigations investigating genetic predictors of susceptibility to anthropophilic dermatophytes (17). As a result, finding genes that cause higher susceptibility to dermatophytosis is difficult, because the pathogen–host interaction should be addressed holistically (10, 28).

Abdel-Rahman and Preuett (108) used successful approaches for identifying genes involved in host–pathogen interactions and hence linked with greater susceptibility to dermatophyte infections. An exhaustive search for genes that may be connected to infection was carried out as part of a genome-wide association research in a cohort of children whose tinea capitis infection was tracked longitudinally over several years. The study included 20 children with *T. tonsurans* > 90% of the time and 20 children with the fungus less than 10% of the time. In general, the scientists discovered 21 genes with a genotype linked to fungal carriage, albeit they did not investigate whether this was linked to tinea capitis symptoms. The genes identified in this study were linked to a variety of tasks, including leukocyte activity, extracellular matrix remodeling, wound healing, and cutaneous permeability. Over 60% of the diversity in infection rate was accounted for by the risk score given to the genotypes in these 21 genes, and eight of the investigated genes appeared to account for the bulk of the observed heterogeneity in susceptibility to dermatophyte infections (108). These data suggest that a genetically defined impairment in adaptive immune responses may influence dermatophyte infection susceptibility. Furthermore, research findings have suggested probable interactions in prevalence, i.e., a failure in the innate response may impede the adaptive response, increasing vulnerability (19, 43, 109, 110).

T. rubrum dermatophytosis was linked to the expression of genes encoding IL-22, human-defensin 2 (hBD-2), and 4-defensin, according to Jaradat et al. (109). (DEFB4). The researchers discovered a link between the number of copies of DEFB4 mRNA and the incidence of *T. rubrum*–induced superficial dermatophytosis. The authors postulated that a low DEFB4 copy number, in combination with high IL-22 levels, was a risk factor for dermatophytosis pathogenesis. Other dermatophytosis candidate genes, such as the Fc receptor gamma, which is exploited by the pattern recognition receptor dectin-2 to promote innate immune responses against *T. rubrum* (111, 112), have been discovered in other research. This gene has been shown to have a varied number of copies in persons with and without infections, suggesting that it may play a role in dermatophyte infection pathogenesis.

CLEC7A-Y238X, an early stop codon variation that alters the detection of fungal-glucan by the receptor dectin-1, was identified in other investigations of a potential gene for susceptibility in individuals suffering from superficial dermatophytosis (113). Dectin-1 surface expression defects caused by the Tyr238X polymorphism resulted in-glucan recognition failure and cytokine response impairment in monocytes and macrophages (114). Because this polymorphism was found in all African communities studied, it is most likely an old mutation that first appeared more than 60,000 years ago, before the separation of modern human lineages in the late Paleolithic (115). In Europe, a genetic abnormality was discovered in a Dutch family with onychomycosis affecting all members (113).

The Human Genome Diversity Project (HGDP) can help elucidate the genetic susceptibility to dermatophytoses and give further information on the frequency and global distribution of genomic polymorphisms linked to dermatophytosis prevalence (116). By investigating genome-wide polymorphism databases, such investigations of haplotype diversity within the white population and other races, families, and populations will undoubtedly discover more genes that are crucial to enhanced sensitivity (43-267).

Conclusion

The heterogeneity of dermatophytes and their hosts suggests that infection susceptibility is most likely the result of alterations on both sides and reciprocal adaptation. Furthermore, a role for host genetics in the development of sickness has been discovered in several investigations, including probable Mendelian inheritance patterns for dermatophytosis propensity. The intricacy of the genetic connection between dermatophytes and their natural and unintentional hosts is underlined in this review. Different theories and approaches may lead to diverse interpretations of this link, according to a literature review. A vital step in better understanding these diseases is selecting an appropriate model for analysis and reasoning. There is also a large sector dedicated to studying the host's genetic and immunological response to dermatophyte infection.

In order to identify the main factors mediating infection risk that can be targeted to disrupt host-pathogen interactions and used in therapies, future studies will require a broader exploration of the dermatophyte genome in combination with analysis of large phenotypically well-characterized populations of various dermatophyte species. As a result, significant research on the relationships between dermatophytes and their unique hosts, which include complicated molecular pathways, is important both theoretically and practically. However, it is certain that genetic predisposition plays a significant role in dermatophyte infection susceptibility.

References

1. Abdelhamid, H. N., M. Dowaidar, M. Hällbrink, and Ü. Langel. 2019. Cell Penetrating Peptides-Hierarchical Porous Zeolitic Imidazolate Frameworks Nanoparticles: An Efficient Gene Delivery Platform. SSRN Electron. J. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3435895.
2. Abdelhamid, Hani Nasser, Moataz Dowaidar, Mattias Hällbrink, and Ülo Langel. 2020. Gene Delivery Using Cell Penetrating Peptides-Zeolitic Imidazolate Frameworks. Microporous and Mesoporous Materials: The Official Journal of the International Zeolite Association 300 (June): 110173. <https://doi.org/10.1016/j.micromeso.2020.110173>.
3. Abdelhamid, Hani Nasser, Moataz Dowaidar, and Ülo Langel. 2020. Carbonized Chitosan Encapsulated Hierarchical Porous Zeolitic Imidazolate Frameworks Nanoparticles for Gene Delivery. Microporous and Mesoporous Materials: The Official Journal of the International Zeolite Association 302 (August): 110200. <https://doi.org/10.1016/j.micromeso.2020.110200>.
4. Ahmad, Almaman, Khalaf Hassan, Rasool Semaab, Moataz Dowaidar, and Al Orainy Mohammad. 2013. The Impact of CYP2C19 Polymorphism on Platelet Reactivity for Guiding Clopidogrel Treatment and Cost Analysis. Journal of the Saudi Heart Association 25 (2): 107. <https://doi.org/10.1016/j.jsha.2013.03.005>.
5. Algahsham, Abdullah, Ahmad A. A. Settin, Ahmad Ali, and Hisham Ismail. n.d. Association of MTHFR C677T and A1298C Polymorphisms with Hypertension among Saudi Subjects from Qassim Region. International Journal of Health Sciences 6 (1). Accessed June 18, 2021. <http://ijhs.org.sa/index.php/journal/article/view/312>.
6. Algasham, Abdullah, Hisham Ismail, Moataz Dowaidar, and Ahmad A. Settin. 2011. Methylenetetrahydrofolate Reductase (MTHFR) and Angiotensin Converting Enzyme (ACE) Gene Polymorphisms among Saudi Population from Qassim Region. International Journal of Health Sciences 5 (2 Suppl 1): 3–4. <https://www.ncbi.nlm.nih.gov/pubmed/23284552>.
7. Alghasham, Abdullah, Ahmad Ali, Hisham Ismail, Moataz Dowaidar, and Ahmad A. Settin. 2012. CYP2J2 -50 G/T and ADRB2 G46A Gene Polymorphisms in Saudi Subjects with Hypertension. Genetic Testing and Molecular Biomarkers 16 (9): 1027–31. <https://doi.org/10.1089/gtmb.2012.0006>.
8. Alghasham, Abdullah, Ahmad A. Settin, Ahmad Ali, Moataz Dowaidar, and Hisham Ismail. 2012a. Association of MTHFR C677T and A1298C Gene Polymorphisms with Hypertension. International Journal of Health Sciences 6 (1): 3–11. <https://doi.org/10.12816/0005968>.
9. Moataz Dowaidar. 2012b. Association of MTHFR C677T and A1298C Gene Polymorphisms with Hypertension. International Journal of Health Sciences 6 (1): 3–11. <https://doi.org/10.12816/0005968>.
10. Ali, Ahmad, Abdullah Alghasham, Hisham Ismail, Moataz Dowaidar, and Ahmad Settin. 2013. ACE I/D and eNOS E298D Gene Polymorphisms in Saudi Subjects with Hypertension. Journal of the Renin-Angiotensin-Aldosterone System: JRAAS 14 (4): 348–53. <https://doi.org/10.1177/1470320312459976>.
11. Ali, Ahmed A. A., Nahla M. Wassim, Moataz M. Dowaidar, and Ahmed E. Yaseen. 2013. Genetic Polymorphism of CYP2D6 Gene among Egyptian Hypertensive Cases. The Journal of Basic & Applied Zoology 66 (4): 228–33. <https://doi.org/10.1016/j.jobaz.2012.12.002>.
12. Ali, Ahmed A. A., Nahla M. Wassim, Moataz Dowaidar, and Ahmed E. Yaseen. 2013b. Association of eNOS (E298D) and CYP2J2 (–50G/T) Gene Polymorphisms with Hypertension among Egyptian Cases. The Journal of Basic & Applied Zoology 66 (4): 234–41. <https://doi.org/10.1016/j.jobaz.2012.12.001>.
13. Moataz Dowaidar. 2013. Association of eNOS (E298D) and CYP2J2 (–50G/T) Gene Polymorphisms with Hypertension among Egyptian Cases. The Journal of Basic & Applied Zoology 66 (4): 234–41. <https://doi.org/10.1016/j.jobaz.2012.12.001>.
14. Aljarallah, Badr, Ahmed Ali, Moataz Dowaidar, and Ahmad Settin. 2011. Prevalence of α -1-Antitrypsin Gene Mutations in Saudi Arabia. Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association 17 (4): 256–60. <https://doi.org/10.4103/1319-3767.82580>.
15. Dowaidar, M., J. Regberg, D. A. Dobchev, and T. Lehto. 2017. Refinement of a Quantitative Structure–activity Relationship Model for Prediction of Cell-Penetrating Peptide Based Transfection Systems. International Journal of. <https://link.springer.com/content/pdf/10.1007/s10989-016-9542-8.pdf>.
16. Dowaidar, Moataz. 2017. In-Silico Design of Peptide-Based Transfection Systems, in-Vitro Validation, and up-Take Pathways Investigation. Department of Neurochemistry, Stockholm University.
17. Moataz Dowaidar. 2018. Chimeric Gene Delivery Vectors : Design, Synthesis, and Mechanisms from Transcriptomics Analysis. Department of Biochemistry and Biophysics, Stockholm University. <https://www.diva-portal.org/smash/record.jsf?pid=diva2:1242000>.
18. Moataz Dowaidar. Cardiometabolic Conditions Could Be Related to Vitamin D Deficiency. The Genetic Determinants That Affect Vitamin D Pathways May Be Solved with Nanomedicines. <https://doi.org/10.31219/osf.io/nqewr>.

19. Moataz Dowaidar. Different Insulin Resistance and Inflammation Pathways Are Influenced by Genetic Factors in Metabolic Syndrome. Gene Therapy Enables Early Recognition and Treatment of the Genetic Factors. <https://doi.org/10.31219/osf.io/gqwj2>.
20. Moataz Dowaidar. Gene Therapy Has Been Shown to Be Valuable for Understanding Complex Disease Pathophysiologies. The Medical Profession as a Whole Will Have to Invest in Specialized Investigations. <https://doi.org/10.31219/osf.io/8fg9y>.
21. Moataz Dowaidar. Genetic and Epigenetic Discoveries Hold Promising Avenues in Cardiovascular Prevention and Management (CVDs). Key Nucleic Acids Are Being Researched and Developed for Medicinal Use. <https://doi.org/10.31219/osf.io/hk7pe>.
22. Moataz Dowaidar. Genome Editing Can Now Be Carried out in an Isogenic Setting. It Can Be Effectively Transmitted to Somatic Tissues in Mice, but Not to Humans. Despite These Doubts, CRIS Has Great Potential as a Medical Promise. <https://doi.org/10.31219/osf.io/4m3v>.
23. Moataz Dowaidar. Genome-Wide Association Experiments Have Uncovered a Slew of Cardiometabolic Trait-Associated Variants. This Information Can Be Useful in the Implementation of New Diagnostic and Treatment Strategies. <https://doi.org/10.31219/osf.io/4vws8>.
24. Moataz Dowaidar. Genome-Wide Association Studies (GWAS) Have Revolutionized Our View of Human Health and Disease Genetics and Offered Novel Gene Therapy Targets. <https://doi.org/10.31219/osf.io/rvm3z>.
25. Moataz Dowaidar. Metabolic Syndrome_ the Presence of Inflammatory Mechanisms in Abdominal Obesity Is Undeniable, Gene Therapy Using Nanoparticles and Adenoviruses Technologies Is Promising. <https://doi.org/10.31219/osf.io/2j5xt>.
26. Moataz Dowaidar. miRNAs May Be Used as Preventive Agents for Metabolic Diseases in the near Future. Understanding the Interplay between pro-Adipogenic_ and Anti-Ad Pipogenic miRNA' Could Lead to New Biomarkers. <https://doi.org/10.31219/osf.io/3dr8c>.
27. Moataz Dowaidar. Nanomedicine Has Elegantly Attempted to Cure Multiple Gene Polymorphisms and Mutations in Cardiovascular Diseases Using Gene Therapy Techniques. <https://doi.org/10.31219/osf.io/d3x8g>.
28. Moataz Dowaidar. Thrombosis Pathways and Therapeutic Strategies. <https://doi.org/10.31219/osf.io/57vyz>.
29. Moataz Dowaidar. What Genomic Research Has Told Us about the Obesity and Its Possible Gene Therapy Targets. <https://doi.org/10.31219/osf.io/ym49s>.
30. Moataz Dowaidar. Exosomes Can Make the Use of Circulating miRNA as a Biomarker More Feasible. The Aim of Gene Therapy Should Be to Learn Everything There Is to Know about miRNA Activity. <https://doi.org/10.31219/osf.io/edkua>.
31. Moataz Dowaidar. Anti-Sense Pathways Have Been Generated Using siRNA. The Liver and Other Often Used Organs Will Now Be Targeted. <https://doi.org/10.31219/osf.io/m6xvp>.
32. Moataz Dowaidar. CrisPR/CRIS Systems Are Highly Effective and Useful for Genomic Manipulation. Despite This, Cardiac Treatment Remains Difficult due to Existing Genome Editing and Delivery Processes. <https://doi.org/10.31219/osf.io/3nwzd>.
33. Moataz Dowaidar. Discoveries in Gene-Environment Interactions That Influence CVD, Lipid Traits, Obesity, Diabetes, and Hypertension Appear to Be Able to Influence Gene Therapy. <https://doi.org/10.31219/osf.io/cr5af>.
34. Moataz Dowaidar. Genome Editing's Potential Target Diseases in the Cardiovascular Field. <https://doi.org/10.31219/osf.io/gc23p>.
35. Moataz Dowaidar. Key Genetic Factors in the Metabolic Syndrome Predisposition Which May Be a Therapeutic Options by Gene Therapy. <https://doi.org/10.31219/osf.io/f38sk>.
36. Moataz Dowaidar. miRNA Can Be a Part of Both the Onset and Cure of Coronary Heart Disease. <https://doi.org/10.31219/osf.io/teqh8>.
37. Moataz Dowaidar. Preclinical Studies and Clinical Trials Have Sparked Interest in Certain Biological Medications for Atherosclerotic Coronary Heart Disease. <https://doi.org/10.31219/osf.io/ts8mh>.
38. Moataz Dowaidar. Researchers Would Be Able to Develop a Detailed Picture of Chromatin in Disease, Which Would Be Useful for Gene Therapy. <https://doi.org/10.31219/osf.io/m9z48>.
39. Moataz Dowaidar. The Cardiometabolic-Based Chronic Disease Model Lays the Foundations for Accurate, Evidence-Based Preventive Targeting and Gene Therapy. <https://doi.org/10.31219/osf.io/up9z4>.
40. Moataz Dowaidar. 2D MOFs Have Unique Features for Biological Applications. They Can Be Utilized for Gene Therapy, Bioimaging, Biosensing, Photodynamic Therapy, and Tissue Engineering. <https://doi.org/10.31219/osf.io/4q9ct>.
41. Moataz Dowaidar. 3D Bioprinting for Enhanced Vascularization, and Gene Editing to Provide a More Favorable Immunological Response Are Just Some of the Potential Uses of Carbon Materials. <https://doi.org/10.31219/osf.io/v2xy8>.
42. Moataz Dowaidar. Anderson–Fabry Disease Can Be a Target for Gene Therapy. <https://doi.org/10.31219/osf.io/tcgka>.
43. Moataz Dowaidar. Antisense Oligonucleotides (ASOs) and CRISPR Systems Are Promising Gene Therapy Treatments for Alzheimer's Disease. <https://doi.org/10.31219/osf.io/ws796>.

44. Moataz Dowaidar. Any Alteration in PPAR Genomic Sequence, Splicing Pattern, or PTM Is Likely to Cause Major Alterations in Its Function. In Personalized Medicine, Such Data Becomes More Significant in Gene Therapy Design. <https://doi.org/10.31219/osf.io/y8n79>.
45. Moataz Dowaidar. Applying Genome-Wide Association Technology to Brain Diseases Enables the Discovery of lncRNAs Targets for Gene Therapy. <https://doi.org/10.31219/osf.io/hm4eu>.
46. Moataz Dowaidar. Autophagy and Proteostasis Adjustment Role in Normal Brain Function and Neurodegenerative Disorders. <https://doi.org/10.31219/osf.io/m4yra>.
47. Moataz Dowaidar. Basal Ganglia-Cerebellar and Brainstem-Cerebellar Circuits May Interact Improperly with Dystonia. Linking Network Disruptions to Cell Failure Will Enable Understanding Pathophysiology and Designing Gene Therapy Methods. <https://doi.org/10.31219/osf.io/8w35s>.
48. Moataz Dowaidar. Blood Products Are Used to Treat a Multitude of Diseases, so the Blood Transfusion System Needs to Be Enhanced. CRISPR/Cas9 Has Made It Viable to Make HLA Class I-Deleted Blood Products to Avoid Rejection. <https://doi.org/10.31219/osf.io/egr3n>.
49. Moataz Dowaidar. Calixarenes (CAs) Are Promising in Biomedicine, Biosensing, Bioimaging and Gene Delivery Systems. <https://doi.org/10.31219/osf.io/n9vjy>.
50. Moataz Dowaidar. CAR T Cell Research Has Quickly Advanced from the Bench to the Clinic and Back. The Results of the Trials Have Revealed New Mechanisms. <https://doi.org/10.31219/osf.io/f9wm7>.
51. Moataz Dowaidar. CAR T-Cell Treatment Remains Clinically Challenging. Therapeutic Strategies May Be Designed to Cut off Immunotherapy Utilizing Safety Switches. <https://doi.org/10.31219/osf.io/s7x4y>.
52. Moataz Dowaidar. Central Nervous System Gene Therapy Has Entered a New Development Paradigm. New Techniques Are Being Employed for a Wide Range of Illness Indications and Pathways. <https://doi.org/10.31219/osf.io/j49wz>.
53. Moataz Dowaidar. Chronic Obstructive Pulmonary Condition (COPD) Is a Prevalent, Preventable, and Curable Illness with Persistent Respiratory Symptoms and Airflow Limitation. <https://doi.org/10.31219/osf.io/vkdut>.
54. Moataz Dowaidar. CircRNAs Have the Potential to Aid in the Diagnosis and Treatment of Lipid Diseases. <https://doi.org/10.31219/osf.io/y3hp4>.
55. Moataz Dowaidar. Clinical Symptoms, Underlying Pathogenesis, and the Prospect of Tailored Therapies Have All Benefited from Genetic Discoveries in Parkinson's Disease. <https://doi.org/10.31219/osf.io/pdzqb>.
56. Moataz Dowaidar. Code Distribution of siRNA for Cancer Genes such as p53 and Bcl2 Family Genes Has Demonstrated Efficacy in Killing Cancer Cells. Nanoparticles Can Produce a Surface Where Numerous Drugs May Be Coupled, Allowing Combinatory Treatment. <https://doi.org/10.31219/osf.io/hvcse>.
57. Moataz Dowaidar. Cognitive Deficiencies Pathophysiology Are Mainly an Unknown Area. Curing the Neurological Conditions Could Be an Objective for Gene Therapy. <https://doi.org/10.31219/osf.io/23xf8>.
58. Moataz Dowaidar. CRISPR-Based Gene Editing Is Presently Being Tried in Many Clinical Trials. <https://doi.org/10.31219/osf.io/qbngx>.
59. Moataz Dowaidar. CRISPR-Cas9 Gene Editing as a Tool for Developing Immunotherapy for Cancer. <https://doi.org/10.31219/osf.io/dvr4t>.
60. Moataz Dowaidar. CRISPR/Cas System Research Has Advanced Significantly in Biological sciences. There Are Still Many Challenges to Effective Delivery before Efficient Gene Editing May Be Achieved. <https://doi.org/10.31219/osf.io/mc26v>.
61. Moataz Dowaidar. CRISPR/Cas9 Genome Editing Technology Applications in Biological and Biomedical Fields. <https://doi.org/10.31219/osf.io/ctqbe>.
62. Moataz Dowaidar. Critical Limb Ischemia Potential Gene Therapy Strategies. <https://doi.org/10.31219/osf.io/aqcpt>.
63. Moataz Dowaidar. Deep Learning Algorithms for scRNAseq Analysis Have Yielded Positive Results, but There Are Still More Promising Ways That Need to Be Developed for Regenerative Medicine. <https://doi.org/10.31219/osf.io/dh2pt>.
64. Moataz Dowaidar. Depression May Be Epigenetically Controlled by miRNAs Making It a Diagnostic or Gene Therapy Target. <https://doi.org/10.31219/osf.io/fw65m>.
65. Moataz Dowaidar. Dermatophytes: Role of Host Genetics in the Development of Illness. <https://doi.org/10.31219/osf.io/mf3bu>.
66. Moataz Dowaidar. Developments in Biomedical Technology Will Increase the Importance of mRNA in Treating Brain Tumors, as Well as Other Malignancies. <https://doi.org/10.31219/osf.io/tvj5x>.
67. Moataz Dowaidar. Downstream Processing of Virus, Virus-like Particles and Nanoparticulate Inclusion Bodies to Be Used as Gene Delivery Vehicles for Human Gene Therapy Applications. <https://doi.org/10.31219/osf.io/exa3q>.
68. Moataz Dowaidar. Dravet Syndrome Is a Severe Developmental and Epileptic Encephalopathy. Fenfluramine and Gene Therapy Are Promising. <https://doi.org/10.31219/osf.io/zvq8y>.
69. Moataz Dowaidar. Exosomes' Function in Cardiovascular Protection and Neovascularization Implies That They Might Be Used to Treat Ischemia and Atherosclerotic Cardiovascular Diseases. <https://doi.org/10.31219/osf.io/2h8c7>.

70. Moataz Dowaidar. Ferropsis Cell Death Can Cause Complications That May Be Difficult to Detect and Quantify: Autophagy Role and Possible Therapeutics. <https://doi.org/10.31219/osf.io/zd2jg>.
71. Moataz Dowaidar. Following the Discovery of Anti-MDA5 Ab, the Clinical Understanding of Dermatomyositis Has Been Improved. <https://doi.org/10.31219/osf.io/j2t5f>.
72. Moataz Dowaidar. For the Treatment of Cystic Fibrosis, RNA Medicines, Gene Transfer Therapies, and Gene Editing Treatments Have Potential. <https://doi.org/10.31219/osf.io/6afzm>.
73. Moataz Dowaidar. Frontotemporal Dementia Is a Complex Disorder with a Wide Spectrum of Clinical Symptoms. Personalized Medicine and Gene Therapy Are Promising Strategies for Treatment. <https://doi.org/10.31219/osf.io/gh4x7>.
74. Moataz Dowaidar. G6PD Deficiency Is a Common Genetic Trait That Can Protect Heterozygotes from Dying from Malaria. <https://doi.org/10.31219/osf.io/g2kza>.
75. Moataz Dowaidar. Gastric Cancer Is the World's Second-Largest Death Cause. Peptides Can Be Used to Deliver Radiation or Other Fatal Chemicals to Tumors. <https://doi.org/10.31219/osf.io/eu5mj>.
76. Moataz Dowaidar. Gene Doping May Be Possible for Lifestyle Enhancement. <https://doi.org/10.31219/osf.io/8xkm5>.
77. Moataz Dowaidar. Gene Expression Assays Gather Evidence That They Can Provide Useful Therapeutic Information in Young Women. <https://doi.org/10.31219/osf.io/d372s>.
78. Moataz Dowaidar. Gene Therapy and Genome-Editing Treatments That Can Protect Patients from Coronary Artery Disease Are under Investigation. <https://doi.org/10.31219/osf.io/xqgf8>.
79. Moataz Dowaidar. Gene Therapy Approaches for Hemophilia A and B. <https://doi.org/10.31219/osf.io/ufc4g>.
80. Moataz Dowaidar. Gene Therapy for the Central Nervous System Has Been Initiated. This Expansion Will Require Some Degree of Simplicity in Delivery Processes. <https://doi.org/10.31219/osf.io/hdy5q>.
81. Moataz Dowaidar. Gene Therapy for the Treatment of Spinal Muscular Atrophy. <https://doi.org/10.31219/osf.io/kpz5f>.
82. Moataz Dowaidar. Gene Therapy May Benefit Inherited Ichthyoses with Concurrent Fungal Infections and Severe Ich Thyroidoses. <https://doi.org/10.31219/osf.io/zxmun>.
83. Moataz Dowaidar. Gene Therapy May Target APOE for Alzheimer's Disease. <https://doi.org/10.31219/osf.io/3y52k>.
84. Moataz Dowaidar. Gene Therapy Promises Accurate, Targeted Administration and Overcoming Drug Resistance in Diverse Cancer Cells. <https://doi.org/10.31219/osf.io/j34n6>.
85. Moataz Dowaidar. Gene Therapy Targeting FVIII, FIX for Haemophilia Treatment. <https://doi.org/10.31219/osf.io/qcbwp>.
86. Moataz Dowaidar. Gene Therapy Targeting PRMT5 May Be Useful in Immunotherapy. <https://doi.org/10.31219/osf.io/gkw8j>.
87. Moataz Dowaidar. Gene Therapy Using Extracellular Vesicles Loaded with miRNA Derived from Bone Marrow Mesenchymal Stem Cells Is a Cell-Free Medication Delivery Method Used in a Variety of Diseases. <https://doi.org/10.31219/osf.io/3znvw>.
88. Moataz Dowaidar. Genetic Engineered MSCs Are Attractive Possibilities for Regenerative Stem-Cell Therapy to Treat Several Liver Diseases. <https://doi.org/10.31219/osf.io/4cfrd>.
89. Moataz Dowaidar. Genetic Variants Shared between Alzheimer's Disease and Parkinson's Disease Have Been Discovered in Blood and Brain Samples. Somatic Mosaicism Might Function as an Accelerator. <https://doi.org/10.31219/osf.io/tr58n>.
90. Moataz Dowaidar. Genome-Wide Association Studies Promise to Discover Novel Indicators of Hypertension. Endothelin-Related SNPs Are Currently in Clinical Trials. <https://doi.org/10.31219/osf.io/2n4wa>.
91. Moataz Dowaidar. Gingival and Intraventricular Haemorrhages Are Severe Newborn Diseases Causing Damage to White Matter and Neurological Dysfunction in Surviving Newborns Who Can Benefit from Gene Therapy. <https://doi.org/10.31219/osf.io/qb84p>.
92. Moataz Dowaidar. Glioblastoma Therapeutic Approaches Were Established Utilizing Contemporary Discoveries in Delivering Medicines to the Brain as Smart Nanoparticles for Focused Therapy. <https://doi.org/10.31219/osf.io/db4f6>.
93. Moataz Dowaidar. Haemophilia Gene Therapy Is in Clinical Studies, Making Continuous Safety and Efficacy Testing a Key Emphasis. <https://doi.org/10.31219/osf.io/sa8ny>.
94. Moataz Dowaidar. Hematopoietic Stem Cell Transplantation and Gene Therapy Are the Sole Treatments for Sickle Cell Disease and Other Hemoglobinopathies. <https://doi.org/10.31219/osf.io/v8xqc>.
95. Moataz Dowaidar. Huntington's Disease Gene Therapy and Nanomedicines May Be Available Shortly. <https://doi.org/10.31219/osf.io/rxvgd>.
96. Moataz Dowaidar. Hybrid Gene Therapy Designed to Fully Understand the Underlying Molecular Cancer Process May Be a Feasible Option. <https://doi.org/10.31219/osf.io/ajyfd>.
97. Moataz Dowaidar. Hydrogels Are Promising Considering Their Incredible Capacity to Modify, Encapsulate and Co-Deliver Medicinal Compounds, Cells, Biomolecules, and Nanomaterials. <https://doi.org/10.31219/osf.io/px3qy>.
98. Moataz Dowaidar. Immune Evasion Is Linked to Histone Variation Malfunction. Gene Therapy Could Provide Tools for Targeting Histone Variant Deposition as a Critical Part of Its Pharmacology. <https://doi.org/10.31219/osf.io/kjm76>.

99. Moataz Dowaidar. Implementing the Human Artificial Chromosome Gene Therapy Platform Remains Challenging, but Continuous Animal Model Research Will Advance the Platform Closer to Clinical Trials. <https://doi.org/10.31219/osf.io/a53f7>.
100. Moataz Dowaidar. Inflammatory Breast Cancer Remains the Most Aggressive Form of Breast Cancer. A Multimodality Therapeutic Plan Has Shown Improved Survival Results. <https://doi.org/10.31219/osf.io/cr935>.
101. Moataz Dowaidar. Inherited Immunohematological and Metabolic Diseases Have the Potential to Improve Significantly, or Be Cured, Using Haematopoietic Stem Cell Transplantation Gene Therapy. <https://doi.org/10.31219/osf.io/ukbnm>.
102. Moataz Dowaidar. Insulin and IGF-1 Receptors Mutations Can Lead to Targets for Gene Therapy in Diabetes, Obesity, and Metabolic Syndrome. <https://doi.org/10.31219/osf.io/s86x5>.
103. Moataz Dowaidar. Integrating High-Throughput Genetics and Neuroimaging Technologies Promises Greater Information on Neurobiological Anomalies in Neurodegenerative Diseases. <https://doi.org/10.31219/osf.io/hpgyz>.
104. Moataz Dowaidar. Intravitreal and Subretinal Injections Currently Deliver Most Gene Therapy, Including siRNA for Eye Illnesses. Non-Viral Vectors May Provide Targeting. <https://doi.org/10.31219/osf.io/rjkhy>.
105. Moataz Dowaidar. LncRNA Regulating Reprogramming Glucose Metabolism Has Become One of the Most Tempting Antineoplastic Targets for Gene Therapy. <https://doi.org/10.31219/osf.io/hqma5>.
106. Moataz Dowaidar. lncRNAs Are Upregulated and Downregulated in OS Cells. Angiogenesis, Metastasis, Cell Signaling, Autophagy, and Death Are among Biological Processes That RNAs Play a Role in. <https://doi.org/10.31219/osf.io/48n7q>.
107. Moataz Dowaidar. Magnetic Nanoparticles Are Widely Used in Drug Delivery, Imaging, Diagnosis, and Targeting. It Has Promises for the Treatment of Inflammatory Disorders such as Rheumatoid Arthritis. <https://doi.org/10.31219/osf.io/p2gme>.
108. Moataz Dowaidar. Many miRNAs Participate in Inflammatory Regulation and Bone Metabolism. Overexpression of miR21 and miR155 Releases Proinflammatory Cytokines. <https://doi.org/10.31219/osf.io/2wuvp>.
109. Moataz Dowaidar. MiR490's Diagnostic Capacity Was Demonstrated in Various Cancer Kinds and Diseases, Adding to Its Clinical Value. <https://doi.org/10.31219/osf.io/wysre>.
110. Moataz Dowaidar. miRNAs Have an Impact on Xeno-Infectious Diseases by Influencing Host And/or Infection Factors. <https://doi.org/10.31219/osf.io/7qewx>.
111. Moataz Dowaidar. Mutations in MED12 Lead to Mental Retardation, Including Opitz–Kaveggia Syndrome, Ohdo Syndrome, Lujan–Fryns Syndrome, and Psychosis. It's a Target for Gene Therapy. <https://doi.org/10.31219/osf.io/cyns8>.
112. Moataz Dowaidar. Nanocarriers Can Be Used to Control the Activity of Genome Editing in a Spatiotemporal Way by Using Stimulusresponsive Nanocarriers. <https://doi.org/10.31219/osf.io/nua89>.
113. Moataz Dowaidar. Nanomaterials Were Formed into Various Shapes, with Functionalization Aimed at Various Internalization Processes. Their Nanoscale Size Allows Drugs to Reach Cells or Extracellular Environments. <https://doi.org/10.31219/osf.io/p2ajv>.
114. Moataz Dowaidar. Nanomedicine Is Offering Promising Strategies for Tumor Blockade Treatment. <https://doi.org/10.31219/osf.io/yzxuq>.
115. Moataz Dowaidar. Network Medicine Might Lead to New Treatments for Dyslipidemia. It Will Be a Challenging Method to Implement in a Clinical Context. <https://doi.org/10.31219/osf.io/nksbw>.
116. Moataz Dowaidar. Neuroinflammation Caused by Activated Microglia and Astrocytes Can Contribute to the Progression of Pathogenic Damage to Substantia Nigra Neurons, Playing a Role in Parkinson's Disease Progression. <https://doi.org/10.31219/osf.io/ac896>.
117. Moataz Dowaidar. Neurologists Rarely Perform Genetic Testing for Parkinson's Disease. Evidence Suggests That Many Patients with Major Genetic Variants Go Undiagnosed. <https://doi.org/10.31219/osf.io/ykpb2>.
118. Moataz Dowaidar. Neuronal Intranuclear Hyaline Inclusion Disease Is a Neurodegenerative Condition Which Can Be a Target for Gene Therapy. <https://doi.org/10.31219/osf.io/upgqd>.
119. Moataz Dowaidar. New Therapies Aim at Restoring the Molecular, Morphological, and Functional Integrity of Parkinson's Specific Brain Circuits. <https://doi.org/10.31219/osf.io/dvyxc>.
120. Moataz Dowaidar. Not All lncMIRHG's Are 'Junk Transcripts,'. lncMIRHG Loci May Make Both Functional miRNAs and lncRNAs, Which Can Work Together or Separately. <https://doi.org/10.31219/osf.io/a567w>.
121. Moataz Dowaidar. Nrf2 Signaling Pathways Are Part of a Wider Network of Signaling Pathways Regulating Thymoquinone Therapeutic Actions Which Need Innovative Formulations and Delivery Methods. <https://doi.org/10.31219/osf.io/u2fa7>.
122. Moataz Dowaidar. Omics Should Be Integrated with Genomics to Uncover Molecular Networks and Tissue and Single-Cell Epigenetic Changes. With These Findings, Targeted Pseudoexfoliation Syndrome and Glaucoma Gene Therapy Procedures May Be Viable. <https://doi.org/10.31219/osf.io/48fj5>.
123. Moataz Dowaidar. Ophthalmic Gene and Cell Therapies. <https://doi.org/10.31219/osf.io/n84m9>.

124. Moataz Dowaidar. P21 Is a Flexible, Multi-Functional Protein. It Governs Various Tumor Cell Activities, Including Autophagy. p21 Is a Possible Radiotherapy Target. <https://doi.org/10.31219/osf.io/ydkca>.
125. Moataz Dowaidar. Parkinson's Disease Simulating Complexity via Improving the Identification of Significant Genetic Alterations and Environmental Contaminants Should Be a Priority. <https://doi.org/10.31219/osf.io/pmcu9>.
126. Moataz Dowaidar. Patient-Specific Microphysiology Systems Are Likely to Become a Crucial Aspect of Translational Research and Precision Medicine. <https://doi.org/10.31219/osf.io/bc8fr>.
127. Moataz Dowaidar. Patients with PMD Who Are Thoroughly Screened by Genomic Medicine Have a Considerable Chance of Benefiting Greatly from Whole-Genome Sequencing. <https://doi.org/10.31219/osf.io/dajft>.
128. Moataz Dowaidar. Polydopamine Nanoparticles' Activity and Long-Term Stability Should Be Fully Studied for Gene Therapy Applications. <https://doi.org/10.31219/osf.io/x4nej>.
129. Moataz Dowaidar. Potential Therapeutics for Primary Mitochondrial Disorders. <https://doi.org/10.31219/osf.io/6pz5k>.
130. Moataz Dowaidar. Potentials of Medicinal Nanostructured Diamond Particles and Coatings. <https://doi.org/10.31219/osf.io/h68xz>.
131. Moataz Dowaidar. Preclinical Investigations Revealed Possibilities for Salmonella Tumor Treatment. Bacteria Can Also Be Coupled to Nanomaterials Enabling Drug-Loading, Photocatalytic And/or Magnetic Properties, Using the Bacteria's Net Negative Charge. <https://doi.org/10.31219/osf.io/embqk>.
132. Moataz Dowaidar. Research into P2X Purinergic Receptor Function in Tumor Growth Has Made Substantial Progress with Potential Gene Therapy Targeting. <https://doi.org/10.31219/osf.io/r34fs>.
133. Moataz Dowaidar. RNA Therapies Hold Great Promise for Treating Cancer. High-Throughput Screening Techniques Have Facilitated the Development of RNA Treatments. <https://doi.org/10.31219/osf.io/9vxrb>.
134. Moataz Dowaidar. RNAi Treatment Has Been Shown to Successfully Modify Human-Related Target Gene Expression, Including Cancer. It Has the Capacity to Control Non-Standard Oncogenes, such as Oncogenic lncRNAs. <https://doi.org/10.31219/osf.io/bwqep>.
135. Moataz Dowaidar. RNAs Hold a Lot of Potential When It Comes to Druggable Molecular Targets. <https://doi.org/10.31219/osf.io/2dtxg>.
136. Moataz Dowaidar. Shadow Enhancers' Objective Seems to Be to Establish Robust Growth Patterns Independent of Genetic or Environmental Stress. <https://doi.org/10.31219/osf.io/qfnkp>.
137. Moataz Dowaidar. Sickle Cell Disease Hematopoietic Stem Cell Gene Therapy with Globin Gene Addition Is Promising. <https://doi.org/10.31219/osf.io/j5fkb>.
138. Moataz Dowaidar. Single-Gene Mutations in mtDNA-Associated Proteins Are Unlikely to Be the Main Cause of Sporadic Parkinson's Disease. Cumulative Genetic Variation in Numerous Genes May Be Important in Neurodegeneration and PD Risk. <https://doi.org/10.31219/osf.io/89qte>.
139. Moataz Dowaidar. Small Nuclear Ribonucleoproteins (snRNPs) Based Gene Therapy. <https://doi.org/10.31219/osf.io/c43r9>.
140. Moataz Dowaidar. Studying the Pathologic Mechanisms of Osteoporosis and the Bone Microenvironment May Help Researchers Better Know the Etiology of Rheumatoid Arthritis, Periodontitis, and Multiple Myeloma, as Well as Other Inflammatory and Autoimmune Disorders. <https://doi.org/10.31219/osf.io/t3z6y>.
141. Moataz Dowaidar. Suicide Gene Therapy May Be Effective in the Treatment of Malignant Glioma. <https://doi.org/10.31219/osf.io/vdkst>.
142. Moataz Dowaidar. Synuclein Is a Protein That Is Expressed in Brain Tissue. The Specific Missense Mutation (SNCA) Found in a Family with Parkinson's Disease Is the Cause. Other Diseases Include Alzheimer's Disease and REM Sleep Behavior Disorder. <https://doi.org/10.31219/osf.io/bs8rc>.
143. Moataz Dowaidar. Systems Biology Is a Method for Analyzing Massive Amounts of Multidimensional Data Generated by Omics Technologies. Cross-Validation of the Various Technological Platforms Is Critical. <https://doi.org/10.31219/osf.io/p8vkd>.
144. Moataz Dowaidar. Targeting Mitochondria and Especially Taz Gene Mutation Induces CL May Give Novel Therapeutic Alternatives for Treating Barth Syndrome. <https://doi.org/10.31219/osf.io/unfpy>.
145. Moataz Dowaidar. The Ability to Combine Multiple mRNA Antigens Targeting Multiple Pathogens Simultaneously, and the Robust Immune Responses Are Confirmed in Several Clinical Studies. <https://doi.org/10.31219/osf.io/6qksx>.
146. Moataz Dowaidar. The Cubic Polyhedral Oligomeric Silsesquioxanes Based Hybrid Materials Have a Wide Variety of Applications, Including Drug Administration, Gene Therapy, Biological Imaging, and Bone Regeneration. <https://doi.org/10.31219/osf.io/9peq8>.
147. Moataz Dowaidar. The Development of Tissue Replacement Therapies and Drug Discovery Was a Critical Milestone in Advancing Regenerative Medicine. <https://doi.org/10.31219/osf.io/w9bsm>.
148. Moataz Dowaidar. The Epidemic of COVID-19 Prompted Widespread Use of mRNA Vaccinations. <https://doi.org/10.31219/osf.io/jqws5>.

149. Moataz Dowaidar. The Most Useful and Commonly Available Acute Rejection Surveillance Strategies Are Routine Monitoring of Myocardial Function and Donor-Specific Anti-HLA Abs Monitoring. <https://doi.org/10.31219/osf.io/ebw68>.
150. Moataz Dowaidar. The Protease MBTPS2 Is an Important Regulator of Several Cellular Processes, Especially in Health and Sickness. <https://doi.org/10.31219/osf.io/qyn6h>.
151. Moataz Dowaidar. The Sigma 1 Receptor (S1R) Is a Potential Therapeutic Target for the Treatment of Huntington's Disease. <https://doi.org/10.31219/osf.io/mcefx>.
152. Moataz Dowaidar. The Use of a Network Medicine Approach Might Result in Innovative Strategies for Lowering Coronary Heart Disease and CV Risks. <https://doi.org/10.31219/osf.io/eakg8>.
153. Moataz Dowaidar. The Vasoconstrictor Endothelin System Involvement in Chronic Kidney Diseases Pathogenesis Is Now the Most Often Employed Treatment Method. <https://doi.org/10.31219/osf.io/cnkqy>.
154. Moataz Dowaidar. The VPS35-D620N Mutation Is Associated with Parkinson's Disease and Can Be a Target for Gene Therapy. <https://doi.org/10.31219/osf.io/83sxx>.
155. Moataz Dowaidar. Therapeutics Including Gene Therapy for Osteoarthritis as a Concept. <https://doi.org/10.31219/osf.io/7zsqr>.
156. Moataz Dowaidar. Tissue Hypoxia Has Been Established as a Master Regulator for Alternative Splicing, with Substantial Clinical Consequences and Possibilities for Gene Therapy Targeting. <https://doi.org/10.31219/osf.io/5pbw4>.
157. Moataz Dowaidar. To Rectify Alzheimer's Disease Etiology, Excessive Mitochondrial Division Might Be Stopped or Mitophagy Might Be Promoted. <https://doi.org/10.31219/osf.io/6kdxw>.
158. Moataz Dowaidar. Transcriptomics Is a Rapidly Growing Field That Generates New Data That May Be Used on Its Own or in Combination with Existing Clinical Data for Development of New Therapeutics, Including Gene Therapy. <https://doi.org/10.31219/osf.io/kfr6a>.
159. Moataz Dowaidar. Tumor Microenvironment Has Clinical Significance in Terms of Prognosis and Therapy Prediction. <https://doi.org/10.31219/osf.io/4dz8q>.
160. Moataz Dowaidar. Using AAV as a Gene Delivery Vector in the Neural System Is Effective in Several Animals, such as Nonhuman Primates. <https://doi.org/10.31219/osf.io/ut4fa>.
161. Moataz Dowaidar. Using Pre-Existing Datasets to Combine Published Information with New Metrics Would Help Researchers Construct a Broader Picture of Chromatin in Disease. <https://doi.org/10.31219/osf.io/gsqv5>.
162. Moataz Dowaidar. Virus-like Particles Are Good Nanocarriers for Liquid Biopsy Probes, Imaging Contrast Agents, and Anticancer Medications. <https://doi.org/10.31219/osf.io/xbtka>.
163. Moataz Dowaidar. ZEB1 Controls the Expression of ICAM1, Promoting Monocyte-Macrophage Adhesion and Hence the Formation of Atherosclerotic Lesions. <https://doi.org/10.31219/osf.io/kzjqg>.
164. Moataz Dowaidar. Gene Therapy Development and Legislation. <https://doi.org/10.31219/osf.io/mwb2n>.
165. Moataz Dowaidar. Next-Generation Sequencing Is Now Utilized to Identify Genetic Abnormalities and Develop Gene Therapy. <https://doi.org/10.31219/osf.io/em7xp>.
166. Moataz Dowaidar. Nucleic Acid Designs, Artificial Intelligence for Screening Nanomaterials, and Enhanced Characterization Methods Are Needed to Make Nanomedicine More Successful. <https://doi.org/10.31219/osf.io/2w5aq>.
167. Moataz Dowaidar. Potential Strategies for Cancer Gene Therapy. <https://doi.org/10.31219/osf.io/atcqz>.
168. Moataz Dowaidar. Quantitative Groups Will Be Critical to the Success of Future Gene Therapy Programs. <https://doi.org/10.31219/osf.io/v97ht>.
169. Moataz Dowaidar. The Treatment of Major Human Illnesses with Recombinant Adeno-Associated Virus (rAAV) Has Shown Tremendous Promises. <https://doi.org/10.31219/osf.io/uwa4e>.
170. Moataz Dowaidar. Carbon Nanotubes Have Enormous Potential in Gene Therapy. <https://doi.org/10.31219/osf.io/9bcxk>.
171. Moataz Dowaidar. Charge-Alteration-Based Approaches Can Address the Evolving Needs of Nucleic Acid-Based Gene Therapy, Charge Reversal Techniques Are Also Promising. <https://doi.org/10.31219/osf.io/zwq5h>.
172. Moataz Dowaidar. Chromosome X, the Most Explored Genome-Editing Chromosome, Presents Possibilities for Hemophilia A Treatments. <https://doi.org/10.31219/osf.io/6vsdz>.
173. Moataz Dowaidar. Clinical Investigations Show That siRNA May Be Used to Treat a Variety of Disorders, Including Cancer. <https://doi.org/10.31219/osf.io/fcsgq>.
174. Moataz Dowaidar. Cyclodextrins as Potential Gene Therapy Vectors. <https://doi.org/10.31219/osf.io/zhtsc>.
175. Moataz Dowaidar. Development of Specialized Carriers Capable of Delivering Effective RNAi and siRNA Gene Therapy. <https://doi.org/10.31219/osf.io/3ykwmm>.
176. Moataz Dowaidar. Gene Therapy Can Target Mutations such as BRAF, Which Have Been Shown to Make Tumors More Susceptible to Autophagy Suppression. <https://doi.org/10.31219/osf.io/3gwra>.
177. Moataz Dowaidar. Gene Therapy Vectors Should Enable CRISPR Systems to Accumulate at Disease Sites and Successfully Penetrate Nuclei. <https://doi.org/10.31219/osf.io/xzmmnc>.
178. Moataz Dowaidar. Nanoformulations Can Be Utilized to Deliver Effective siRNA to Tumor Cells to Decrease Gene Expression. <https://doi.org/10.31219/osf.io/zvukc>.

179. Moataz Dowaidar. Neuronal Ceroid Lipofuscinosis Therapeutics. <https://doi.org/10.31219/osf.io/75vcp>.
180. Moataz Dowaidar. Nonviral Gene Delivery Vectors for Transfection of the CAR Gene for CAR-T Cell Therapy. <https://doi.org/10.31219/osf.io/ckxh5>.
181. Moataz Dowaidar. Potential HIV Gene Therapy Strategies. <https://doi.org/10.31219/osf.io/e5hm2>.
182. Moataz Dowaidar. Research on Cell Sources for Brain Cell Replacement Methods Has Gained Major Importance. Cell and Gene Therapy Are Potentially Intriguing New Domains of Regenerative Medicine. <https://doi.org/10.31219/osf.io/g835b>.
183. Moataz Dowaidar. RNAi-Based Gene Therapy Provides a Wide Variety of Applications. Safe, Biodegradable Nano Delivery Vectors Are Still Needed. <https://doi.org/10.31219/osf.io/s2zhn>.
184. Moataz Dowaidar. Strategies for Treating Multiple Sclerosis with Gene Therapy. <https://doi.org/10.31219/osf.io/sync6>.
185. Moataz Dowaidar. The Combination of Unique Biomolecules and Nanoparticles Has Shown Successful Gene Therapy Treatment Approaches for Non-Small Cell Lung Cancer Treatment. <https://doi.org/10.31219/osf.io/yeq5z>.
186. Moataz Dowaidar. Understanding Why the Same Gene Delivery Vector Behaves Differently in Different Cell Types Is Essential for Developing More Adaptable Transfection Systems. <https://doi.org/10.31219/osf.io/6q8af>.
187. Moataz Dowaidar. AAV9 Is Considered the Most Efficient AAV Serotype Targeting Blood-Brain Barriers. To Enhance Effective Gene Therapy for CNS Illnesses, Testing Novel Vectors with More Efficient Crossing Capabilities Is Vital. <https://doi.org/10.31219/osf.io/7bf5s>.
188. Moataz Dowaidar. Artificial miRNAs Are Potential Gene Therapy Tools, Especially for Incurable Monogenic Disorders. <https://doi.org/10.31219/osf.io/d5rnm>.
189. Moataz Dowaidar. Breakthroughs in mRNA Modification and Nanoparticle-Based Delivery Vehicles Facilitate Gene Therapy Strategies. <https://doi.org/10.31219/osf.io/ky7dt>.
190. Moataz Dowaidar. CRISPR/Cas9-Mediated Genome Editing Has Demonstrated Significant Promise for Genetic Correction in Autologous Hematopoietic Stem/progenitor Cells (HSPCs) and Induced Pluripotent Stem Cells (iPSCs). <https://doi.org/10.31219/osf.io/xk54r>.
191. Moataz Dowaidar. Gene Therapy Vectors for Targeting the Heart. <https://doi.org/10.31219/osf.io/gcbhf>.
192. Moataz Dowaidar. Liposomes Can Minimize Cardiotoxicity, Address Drug Resistance, and Improve Overall Drug Release Profiles in Breast Cancer. <https://doi.org/10.31219/osf.io/tn56d>.
193. Moataz Dowaidar. Liposomes with Cerasome-Forming Lipids as Gene Therapy Vectors. <https://doi.org/10.31219/osf.io/zjn6v>.
194. Moataz Dowaidar. Nanomaterials Combine Multiple Therapeutic Approaches for Cancer Cell Multidrug Resistance, Ferroptotic Cell Death Is Promising in Various Cancers. <https://doi.org/10.31219/osf.io/7bg9t>.
195. Moataz Dowaidar. Nanomedicines for Enhanced Permeability and Retention (EPR)-Stratified Patients Have the Potential to Improve Treatment Outcomes. <https://doi.org/10.31219/osf.io/xrcb2>.
196. Moataz Dowaidar. RNA-Based Gene Therapy for Manipulating the Neuroinflammatory Cascade Closely Linked to Neurodegeneration Can Help Reduce Disease Development. <https://doi.org/10.31219/osf.io/2hswv>.
197. Moataz Dowaidar. Targeted Chemical Nucleases Have a Wide Range of Untapped Applications in Biological Fields, Including Gene Therapy. <https://doi.org/10.31219/osf.io/6bexs>.
198. Moataz Dowaidar. Bacterial Nanoparticles Can Deliver Proteins, Medications, Enzymes, and Genes to Diagnose and Cure Numerous Illnesses. <https://doi.org/10.31219/osf.io/7gyna>.
199. Moataz Dowaidar. Exosomal miRNA Diagnostic and Gene Therapy Tools. <https://doi.org/10.31219/osf.io/aknrc>.
200. Moataz Dowaidar. Gene Modification Research Has Potential, from Diagnostic to Therapeutic Levels. The Most Promising Metabolic Pathways Include the TGF-1 Signaling System, Inflammation and Protein Transport. <https://doi.org/10.31219/osf.io/5ert4>.
201. Moataz Dowaidar. Gene Therapy Using MnO₂ Nanoparticles. <https://doi.org/10.31219/osf.io/xmwjs>.
202. Moataz Dowaidar. Gene-Regulatory Elements May Change the Amount, Timing, or Location of Gene Expression, Cis-Regulation Therapy Platforms Might Become a Gene Therapy to Treat Many Genetic Diseases. <https://doi.org/10.31219/osf.io/xk5a2>.
203. Moataz Dowaidar. Hemophilia Therapeutics. <https://doi.org/10.31219/osf.io/gu74x>.
204. Moataz Dowaidar. Mesenchymal Stem Cells Strategies in Cancer Immunotherapy. <https://doi.org/10.31219/osf.io/dkv6w>.
205. Moataz Dowaidar. Nanomaterials Can Inhibit Planktonic and Biofilm Bacteria and Can Be Used as Topical Therapy for Mouth and Wound-Related Infections. <https://doi.org/10.31219/osf.io/aqd2e>.
206. Moataz Dowaidar. New Technologies to Improve CAR T Cell Generation and Biomanufacturing Will Lead to Safer, More Therapeutically Effective Cells. <https://doi.org/10.31219/osf.io/un8gp>.
207. Moataz Dowaidar. Ocular Gene Therapy Strategies. <https://doi.org/10.31219/osf.io/7en3k>.
208. Moataz Dowaidar. Peripheral Nerve Injury Therapeutics, Including Electrical Stimulation, Stem Cell Treatments, and Synthetic Neural Scaffolds, Have Shown Promising Preclinical and Even Clinical Results with Potential Regenerative Treatment. <https://doi.org/10.31219/osf.io/m8cs9>.

209. Moataz Dowaidar. Photothermal and Photodynamic Photoactivation of Nanomaterials-Based Prodrugs Are Two Key Methods for NIR Light-Mediated Photoactivation. <https://doi.org/10.31219/osf.io/2bh3r>.
210. Moataz Dowaidar. Quantum Dots Have the Potential to Be Used in Gene Therapy. <https://doi.org/10.31219/osf.io/bdeg6>.
211. Moataz Dowaidar. Sick Cell Disease Has Emerged as a Public Health Concern. Some Drugs May Conflict with Curative Therapies, yet They May Be Useful as a Bridge to HSCT and Gene Therapy. <https://doi.org/10.31219/osf.io/6kufh>.
212. Moataz Dowaidar. Stimulator of Interferon Genes (STING)-Activating Nanoparticles Can Be Employed as a Tool for Controlled Immune Activation. <https://doi.org/10.31219/osf.io/2ez7a>.
213. Moataz Dowaidar. CRISPR/Cas9 Has Introduced New Gene Therapy Possibilities for Muscular Dystrophies. <https://doi.org/10.31219/osf.io/ug8v4>.
214. Moataz Dowaidar. Degradable Branched Polycationic Systems Are Promising Gene Therapy Vectors. <https://doi.org/10.31219/osf.io/utypf>.
215. Moataz Dowaidar. Developing Nanotechnology Platforms for Peptide-Based Combinatory Cancer Gene Therapy Will Likely Have a Significant Influence on the Development of Personalized Cancer Medicines. <https://doi.org/10.31219/osf.io/zbrkj>.
216. Moataz Dowaidar. Exosomes May Prevent Cardiac Attacks, Heart Failure, and Cardiomyopathy. <https://doi.org/10.31219/osf.io/agm3k>.
217. Moataz Dowaidar. 2021gr. Exosomes Potential Therapeutics. <https://doi.org/10.31219/osf.io/mhwt3>.
218. Moataz Dowaidar. Gene Therapy Using miRNA Treatment Suppresses the Expression of Bone-Forming Defective Genes and Raises the Expression of Genes That Become Dormant during Bone Building. <https://doi.org/10.31219/osf.io/tcka3>.
219. Moataz Dowaidar. Genome-Editing Is Promising for Producing Therapeutically Relevant Animal Models for Possible Therapies for Rare Human Diseases. <https://doi.org/10.31219/osf.io/dehr9>.
220. Moataz Dowaidar. Human Corneal Endothelial Cells Grafts to Replace Cadaveric Donor Corneas. <https://doi.org/10.31219/osf.io/p9x7e>.
221. Moataz Dowaidar. Hybrid Nanotechnology and Peptide Nucleic Acid Could Improve the Effectiveness of Gene Therapy by Increasing Its Cell Permeability. <https://doi.org/10.31219/osf.io/d8wzt>.
222. Moataz Dowaidar. In Prenatal Stem Cell Transplantation and in Utero Gene Therapy, a Wide Spectrum of Genetic Diseases Can Be Diagnosed and Treated before Birth. <https://doi.org/10.31219/osf.io/sa3vz>.
223. Moataz Dowaidar. Magnetic Iron Oxide Nanoparticles Have Potential on Gene Therapy Effectiveness and Biocompatibility. <https://doi.org/10.31219/osf.io/f3hm4>.
224. Moataz Dowaidar. Neurotrophin Gene Therapy May Be Able to Treat Individuals with Noise-Induced Hearing Loss or Neural Presbycusis. <https://doi.org/10.31219/osf.io/spkxh>.
225. Moataz Dowaidar. Plant Viral Nanoparticles Can Be Used in Biological Systems for Loading and Transporting Cargo. <https://doi.org/10.31219/osf.io/txdka>.
226. Moataz Dowaidar. Polydopamine May Be Easily Functionalized with a Range of Nanomaterials for Synergistic Cancer Therapy, in Addition to Its Exceptional Photothermal Effects. <https://doi.org/10.31219/osf.io/cq942>.
227. Moataz Dowaidar. Tumor-Targeted Drug Delivery Systems for Anticancer Therapies Can Selectively Provide an Appropriate Cytotoxic Payload to Cancer Cells, Reducing the Side Effects of Chemo. <https://doi.org/10.31219/osf.io/683nj>.
228. Dowaidar, Moataz, Hani Nasser Abdelhamid, Mattias Hällbrink, Krista Freimann, Kaido Kurrikoff, Xiaodong Zou, and Ülo Langel. 2017. Magnetic Nanoparticle Assisted Self-Assembly of Cell Penetrating Peptides-Oligonucleotides Complexes for Gene Delivery. *Scientific Reports* 7 (1): 9159. <https://doi.org/10.1038/s41598-017-09803-z>.
229. Dowaidar, Moataz, Hani Nasser Abdelhamid, Mattias Hällbrink, Ülo Langel, and Xiaodong Zou. 2018. Supplemental Material for Chitosan Enhances Gene Delivery of Oligonucleotide Complexes with Magnetic Nanoparticles-cell-Penetrating Peptide. *SAGE Journals*. <https://doi.org/10.25384/SAGE.7105436.V1>.
230. Dowaidar, Moataz, Hani Nasser Abdelhamid, Mattias Hällbrink, Xiaodong Zou, and Ülo Langel. 2017. Graphene Oxide Nanosheets in Complex with Cell Penetrating Peptides for Oligonucleotides Delivery General Subjects. *Biochimica et Biophysica Acta, General Subjects*. <https://pubag.nal.usda.gov/catalog/5734174>.
231. Moataz Dowaidar. 2017. Graphene Oxide Nanosheets in Complex with Cell Penetrating Peptides for Oligonucleotides Delivery. *Biochimica et Biophysica Acta, General Subjects* 1861 (9): 2334–41. <https://doi.org/10.1016/j.bbagen.2017.07.002>.
232. Dowaidar, Moataz, and Moataz Dowaidar. 2018. Chimeric Gene Delivery Vectors : Design, Synthesis, and Mechanisms from Transcriptomics Analysis.
233. Moataz Dowaidar. Addiction Biology Research on miRNAs, and Their Role in the Pathophysiology of Addiction Is Enabling Gene Therapy Opportunities. <https://doi.org/10.31219/osf.io/z5wyt>.
234. Moataz Dowaidar. Aptamers Targeting Vascular Endothelial Growth Factor Molecular Regulation as Potential Therapists. <https://doi.org/10.31219/osf.io/a8qpr>.

235. Moataz Dowaidar. Arrhythmogenic Cardiomyopathy Is a Set of Hereditary Cardiac Muscle Disorders Where Various Etiologies Converge. Most ACM Patients Do Not Have a Genetic Diagnosis. <https://doi.org/10.31219/osf.io/pztv3>.
236. Moataz Dowaidar. Autophagy, Immunological Response, and Inflammation All Rely on the TRIM Family Proteins. TRIM-Based Therapeutics for Inflammatory Illnesses Including Diabetes and Diabetic Comorbidities Are Promising. <https://doi.org/10.31219/osf.io/y4g6e>.
237. Moataz Dowaidar. Biogenic Particles Can Be Multiantigenic, Immunostimulative and Activate Innate Immunity While Suppressing Tumor Development. <https://doi.org/10.31219/osf.io/q2kby>.
238. Moataz Dowaidar. Biological Medications for Interventional Pain Have a Lot of Clinical Data behind Them. It Is Fair to Assume They Will Replace Steroid-Based Interventional Techniques, Providing Patients with Longer Relief. <https://doi.org/10.31219/osf.io/4y5fm>.
239. Moataz Dowaidar. Carbon Nanofibers Assist in the Manufacture of Prosthetic Joints, Promote Tissue, Organ, Nerve Regeneration and Development, and Improve Anticancer Therapy Impact and Chemosensitization for a Range of Tumor Types. <https://doi.org/10.31219/osf.io/z3ucn>.
240. Moataz Dowaidar. Emerging Therapy Options May Help Patients with RAG Deficiency, Especially Those with Severe Immune Dysregulation. <https://doi.org/10.31219/osf.io/v5tjg>.
241. Moataz Dowaidar. Exosomes as Promising Gene Therapy Tools Still Need to Be Researched and Manufactured More Efficiently. <https://doi.org/10.31219/osf.io/nw4z7>.
242. Moataz Dowaidar. Focus on Exosomes Could Help Make the Use of Circulating miRNA as Biomarkers More Practical. A Detailed Understanding of miRNA Behavior Should Be a Subject of Gene Therapy. <https://doi.org/10.31219/osf.io/uan6x>.
243. Moataz Dowaidar. Gene-Free Viral-like Particles (VLPs) Offer a Safer Alternative to Inactivating or Weakening Viral Strains for Traditional Vaccines. VLP-Based Vaccinations without Adjuvants Have Been Found to Promote Humoral and Cellular Immunity. <https://doi.org/10.31219/osf.io/9dvut>.
244. Moataz Dowaidar. Given the Importance of mTOR Signaling in a Number of Illnesses, It Looks Suitable to Use miR 99 Family Members as a Therapeutic Intervention to Deal with These Illnesses by Using Gene Therapy Tools. <https://doi.org/10.31219/osf.io/8cwgh>.
245. Moataz Dowaidar. HMGB1 Has Sparked a Lot of Attention as a Model DAMP Molecule Involved in Inflammation, Inflammatory Diseases, and Cancer. <https://doi.org/10.31219/osf.io/5qx36>.
246. Moataz Dowaidar. Nucleic Acid Nanocarriers Can Be Programmable, Spatially Adjustable and Biocompatible, Minimizing Systemic Toxicity and Improving Pharmacodynamics. <https://doi.org/10.31219/osf.io/wr237>.
247. Moataz Dowaidar. Osteoporosis Is a Prominent Source of Morbidity and Mortality in the Elderly, Particularly in Postmenopausal Women. Long Noncoding RNAs (lncRNAs) Have Been Found to Be Important Regulators and Possible Gene Therapy Targets. <https://doi.org/10.31219/osf.io/ghfpt>.
248. Moataz Dowaidar. Polycomb Genes Role in Cancer Pathophysiology Is Offering Targets for Therapeutics Including Gene Therapy. <https://doi.org/10.31219/osf.io/sfvej>.
249. Moataz Dowaidar. RNA Sequencing and Microarray Analysis Are Helpful Techniques to Detect Obesity-Related lncRNAs. lncRNA Can Alter Cholesterol Metabolism and Can Be a Target for Gene Therapy. <https://doi.org/10.31219/osf.io/3fb6w>.
250. Moataz Dowaidar. Sepsis-Associated Acute Kidney Damage Is a Disease That Affects the Patient's Quality of Life. It Should Be a Target for Gene Therapy. <https://doi.org/10.31219/osf.io/49k7q>.
251. Moataz Dowaidar. The Gene Expression Profiling Gives an in-Depth Insight of Breast Cancer Heterogeneity, Better than a Single Protein or Gene Expression. It Is Time to Include It in the Daily Routine. <https://doi.org/10.31219/osf.io/xhyd7>.
252. Moataz Dowaidar. The Nanomedicine System Has Successfully Inhibited Tumor Neovascularization Using Gene Silencing, Chemotherapy, Photothermal Therapy, and Other Therapies. <https://doi.org/10.31219/osf.io/rk2bf>.
253. Moataz Dowaidar. The Therapeutic Application of a Nucleic Acid Sequence to Patients' Diseased Organs Is Currently Available. <https://doi.org/10.31219/osf.io/pqsbfb>.
254. Moataz Dowaidar. Triple-Negative Breast Cancer, Which Lacks the Expression of Hormone Receptors and HER2, Has a Worse Prognosis. Massive Parallel Sequencing Is Capable of Reliably Breaking down the Intra-Tumor and Inter-Tumor Heterogeneity. <https://doi.org/10.31219/osf.io/pvk7u>.
255. Dowaidar, Moataz, H. A. Ismail, A. A. Alghasham, M. M. Dowaidar, and A. A. Settin. 2011. Polymorphisms in MTHF and Ace Genes and the Association with Hypertension among Saudi Population from Qassim Region. *Egyptian Journal of Biochemistry and Molecular Biology* 29 (1). <https://doi.org/10.4314/ejbmb.v29i1.67382>.
256. Dowaidar, Moataz, Hani Nasser Abdelhamid, Mattias Hällbrink, Ülo Langel, and Xiaodong Zou. 2018. Chitosan Enhances Gene Delivery of Oligonucleotide Complexes with Magnetic Nanoparticles-Cell-Penetrating Peptide. *Journal of Biomaterials Applications* 33 (3): 392–401. <https://doi.org/10.1177/0885328218796623>.
257. Dowaidar, Moataz, and Ahmad Settin. 2010. Risk of Myocardial Infarction Related to Factor V Leiden Mutation: A Meta-Analysis. *Genetic Testing and Molecular Biomarkers* 14 (4): 493–98. <https://doi.org/10.1089/gtmb.2010.0017>.

258. Gestin, Maxime, Moataz Dowaidar, and Ülo Langel. 2017. Uptake Mechanism of Cell-Penetrating Peptides. *Advances in Experimental Medicine and Biology* 1030: 255–64. https://doi.org/10.1007/978-3-319-66095-0_11.
259. Ismail, H. A., A. A. Alghasham, M. M. Dowaidar, and A. A. Settin. 2011. Polymorphisms in MTHF and Ace Genes and the Association with Hypertension among Saudi Population from Qassim Region. *Egyptian Journal of Biochemistry and Molecular Biology* 29 (1). <https://doi.org/10.4314/ejbmb.v29i1.67382>.
260. Settin, Ahmad A., Abdullah Algasham, Moataz Dowaidar, and Hisham Ismail. 2009. Methylene Tetrahydrofolate Reductase and Angiotensin Converting Enzyme Gene Polymorphisms Related to Overweight/obesity among Saudi Subjects from Qassim Region. *Disease Markers* 27 (2): 97–102. <https://doi.org/10.3233/DMA-2009-0660>.
261. Settin, Ahmad A., Abdullah Alghasham, Ahmad Ali, Moataz Dowaidar, and Hisham Ismail. 2012. Frequency of Thrombophilic Genetic Polymorphisms among Saudi Subjects Compared with Other Populations. *Hematology* 17 (3): 176–82. <https://doi.org/10.1179/102453312X13376952196575>.
262. Settin, Ahmad, Ibrahim S. Abu-Saif, Rizk El-Baz, Moataz Dowaidar, Rabab Abu-Al Kasim, and Shaimaa Shabana. 2007a. Diagnosis of Sex Chromosome Disorders and Prenatal Diagnosis of Down Syndrome Using Interphase Fluorescent In-Situ Hybridization Technique. *International Journal of Health Sciences* 1 (2): 203–9. <https://www.ncbi.nlm.nih.gov/pubmed/21475429>.
263. Settin, Ahmad, Abdullah Algasham, Moataz Dowaidar, and Hisham Ismail. 2011. Methylene Tetrahydrofolate Reductase (MTHFR) and Angiotensinogen Converting Enzyme (ACE) Gene Polymorphisms Related to Overweight and Obesity among Saudi Patients in Al Qassim. *International Journal of Health Sciences* 5 (2 Suppl 1): 24–25. <https://www.ncbi.nlm.nih.gov/pubmed/23284565>.
264. Settin, Ahmad, Hala Almarsafawy, Ahmad Alhussieny, and Moataz Dowaidar. 2008a. Dysmorphic Features, Consanguinity and Cytogenetic Pattern of Congenital Heart Diseases: A Pilot Study from Mansoura Locality, Egypt. *International Journal of Health Sciences* 2 (2): 101–11. <https://www.ncbi.nlm.nih.gov/pubmed/21475491>.
265. Settin, Ahmad, Moataz Dowaidar, Rizk El-Baz, Ayman Abd-Al-Samad, Ibrahim El-Sayed, and Mahmoud Nasr. 2008. Frequency of Factor V Leiden Mutation in Egyptian Cases with Myocardial Infarction. *Hematology* 13 (3): 170–74. <https://doi.org/10.1179/102453308X316158>.
266. Venit, Tomas, Moataz Dowaidar, Maxime Gestin, Syed Raza Mahmood, Ülo Langel, and Piergiorgio Percipalle. 2020. Transcriptional Profiling Reveals Ribosome Biogenesis, Microtubule Dynamics and Expression of Specific lncRNAs to Be Part of a Common Response to Cell-Penetrating Peptides. *Biomolecules* 10 (11): 1567. <https://doi.org/10.3390/biom10111567>.
267. Dowaidar, M. Cell-Penetrating Peptides Uptake Pathways and Role in Drug Delivery with Potentials for Gene Therapy and Vaccine Development . *Preprints.org* 2023, 2023070889. <https://doi.org/10.20944/preprints202307.0889.v1>